Cost-Effectiveness of 21-Gene Assay in Node-Positive, Early-Stage Breast Cancer
A decision-analytic model was used to estimate cost-effectiveness of adopting a 21-gene assay in treatment decisions for women with early-stage N (1-3)/ER HER2-negative breast cancer.